IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.
about
The use of lentinan for treating gastric cancerInterleukin 12: still a promising candidate for tumor immunotherapy?CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.NK cell-based immunotherapy for malignant diseases.Use of a nanoporous biodegradable miniature device to regulate cytokine release for cancer treatmentThe marginating-pulmonary immune compartment in mice exhibits increased NK cytotoxicity and unique cellular characteristics.TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cellsA phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.Immune therapy for breast cancer in 2010-hype or hope?Super-resolution imaging of remodeled synaptic actin reveals different synergies between NK cell receptors and integrins.Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells.Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.New directions in natural killer cell-based immunotherapy of human cancer.Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.Biology and clinical impact of human natural killer cells.Adding cytokines to monoclonal antibody therapy: does the concurrent administration of interleukin-12 add to the efficacy of rituximab in B-cell non-hodgkin lymphoma?T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survivalTLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy.Genkwadaphnin induces IFN-γ via PKD1/NF-κB/STAT1 dependent pathway in NK-92 cells.A multiscale systems perspective on cancer, immunotherapy, and Interleukin-12Gene expression profiling of the human natural killer cell response to Fc receptor activation: unique enhancement in the presence of interleukin-12.miR-155 regulates IFN-γ production in natural killer cells.Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation.The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune CellsAdjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancerAnalysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response.Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.Rafting with the IL-12 receptor.Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gammaIL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production.NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by CytokinesHuman natural killer cells.Toll-like receptor 2 ligands regulate monocyte Fcγ receptor expression and function.Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patientsEffects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin.Folate-conjugated immunoglobulin targets melanoma tumor cells for NK cell effector functions.Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines.Gene Expression Meta-Analysis Identifies Cytokine Pathways and 5q Aberrations Involved in Metastasis of ERBB2 Amplified and Basal Breast Cancer.
P2860
Q24619416-802C9410-0A69-426E-A049-286275E58638Q26861559-087EB4A3-84A3-4866-B314-725A9EC1CF32Q33677456-A53FE267-C5D0-4EF8-A762-3F3044626DF6Q33827433-C6212651-A536-4AD3-BB1A-1A59764CBAD5Q33828167-79764DAB-2A14-48AE-8ABE-F678435563D7Q33871649-8481FE21-4B84-42EB-A0B3-02AA4BE19CF1Q34076526-E58D6733-DC66-4BE8-8AE9-C3346A7CDFB9Q34382125-473D4037-7E3C-4575-9B8C-4FA8B08BBEF9Q34541467-30BDEE4F-C1AD-4656-8246-6BA558551015Q34548289-67892AB1-19DB-495A-BFAE-1997B761799BQ34672927-04059E5A-5B60-408E-92E5-5F0D80FA1920Q35031732-8439BF51-AD3E-4313-AF60-56AB03F9922CQ35093608-8ACF61FD-0E13-4F5B-BE98-1DEBE0D3AD6EQ35156935-EAF378A0-D1CD-48DD-915C-AE4D0F251A65Q35190471-28D45406-8522-4A94-A654-BDBC709E481EQ35210415-AEF326B8-D23D-48EF-9467-4B4D669F4AA7Q35212682-CC70A337-E380-41EA-B45B-A868C84EB028Q35510560-38A594BD-A371-4A5F-B686-4495B55E2C22Q35527121-AA6FF57F-8ABD-45AB-A556-33993EA01021Q35624686-F51CDEFA-114E-4BFC-A0FB-300F271C4862Q35809223-8D10791F-915E-4D21-A171-ED9220B77788Q35885288-0ABF99E1-FC1A-4FD9-8C14-49E6C45F37EEQ35962555-D3AFA7DF-4AAC-4B85-BF20-F09DE95F1A3EQ35988731-AD1F6ACE-A277-442C-95DA-8E768532AE5AQ36060352-BC7F9A5D-AD0B-4511-B8DC-283BE8A61AD4Q36139709-93528E5E-40F1-4992-BE62-DE9669CB3FFBQ36204962-BB1E185B-B5C3-4D7D-8227-99BFF6DF31AAQ36453386-00439C74-DDD6-4832-BF03-56708DDAC951Q36460314-D8C1C178-2740-418D-B207-E30993DD00E8Q36528716-ACE8ACAD-07E1-4883-93D9-3008F09DE622Q36528782-71F2C15B-BF80-4523-BBD9-62D04DE84BB0Q36671364-B8B1F8E5-2A6A-49EE-8F55-BA8C763D4F0EQ36759187-7D164405-DD2C-42DD-9F15-89362DBF4123Q36787596-9B14FA6D-3126-4313-BFC3-0E9A632CBEDDQ36796964-E8729CBC-B257-4A2F-B959-5331DC6F5A6EQ36806268-3F9F5F13-059E-4270-85C4-662047D1B80FQ37000481-E960B8E6-D58B-4D6F-BB0F-919C566C3FA8Q37053016-B158DB56-8562-4BE5-8DFD-6836F772F809Q37356349-E184795D-6BA6-45E2-9574-75FD8794479CQ37373360-B2FC519E-D2DB-4255-9017-4B96A21C7CF6
P2860
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.
@ast
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.
@en
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.
@nl
type
label
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.
@ast
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.
@en
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.
@nl
prefLabel
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.
@ast
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.
@en
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.
@nl
P2093
P2860
P356
P1476
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.
@en
P2093
Julie Dierksheide
Robin Parihar
William E Carson
P2860
P304
P356
10.1172/JCI0215950
P407
P577
2002-10-01T00:00:00Z